AFTER-HOURS TRADING - BREAKING NEWS
Get Quote -
http://quote.money.cnn.com/quote/quote?symbols=htds
Hard to Treat Diseases Incorporated - HTDS - Announces: Receipt of Tubercin Toxicity Study
and Formation of Scientific Advisory Panel - Wednesday December 3, 8:04 pm ET
DELRAY BEACH, Fla.--(BUSINESS WIRE)--Dec. 3, 2003--Hard to Treat Diseases Incorporated
(Pink Sheets: HTDS) announces today that the spokesperson for the independent medical
group conducting the testing for HTTD (HTDS) has forwarded the formal Testing Results of
Tubercin®'s Toxicity Trials to HTTD.
Tubercin of five different concentrations was administered to five groups of mice. A
pathologist at the University of Oklahoma Health Science Center performed autopsies. The
mice were randomized and only the control mouse was known to the pathologist, as stated in
the cover letter of the Pathology Report.
The report concludes, "All tissues evaluated, visceral organs and the brain were
essentially normal in appearance." "The importance of this report is even better
than I expected," stated the spokesperson for the medical group. "As the testing
continues and if the results are similar to those of Chemotherapy and or radiation with no
harmful side effects, Tubercin has enormous potential for the treatment of cancer and the
immune system."
The President and CEO of HTTD, Mr. Colm J. King is in the process of forming a Scientific
Advisory Panel with leading Oncologists and Immunologists from prestigious institutions in
the U.S. The panel will review the reports and results of Tubercin®'s findings and
will report back to Mr. King with the ongoing reports in layman language for the
shareholders.
"We are continuing to receive promising results regarding Tubercin® and we're
looking forward to additional positive results in the near future," stated Mr. King.
"These tests prove that Tubercin® is non-toxic and is the first step on the way to
human clinical trials as well as the first positive breakthrough conducted in the United
States with an independent medical group for Tubercin®.
Operating out of Delray Beach, Florida, Hard to Treat Diseases Incorporated
("HTTD") holds the international marketing rights, except South Korea, to
Tubercin®, a patented immunostimulant developed for combating Cancer under medical patent
(US Patent 6,274,356). The unique properties unlike other cancer products are clearly
stated in the abstract summary of the patent... "A carbohydrate complex, which is a
mixture of low molecular-weight polysaccharides of an arabinomannan structure extracted
from Mycobacterium tuberculosis, is highly effective in treating various cancer patients
without incurring any adverse side effects."
Statements in this press release that are not historical facts are forward-looking
statements within the meaning of the Securities Act of 1933, as amended. Those statements
include statements regarding the intent, belief or current expectations of the Company and
its management. Such statements reflect management's current views, are based on
certain assumptions and involve risks and uncertainties. Actual results, events, or
performance may differ materially from the above forward-looking statements due to a
number of important factors, and will be dependent upon a variety of factors, including,
but not limited to, our ability to obtain additional financing and access funds from our
existing financing arrangements that will allow us to continue our current and future
operations and whether demand for our product and testing service in domestic and
international markets will continue to expand. The Company undertakes no obligation to
publicly update these forward-looking statements to reflect events or circumstances that
occur after the date hereof or to reflect any change in the Company's expectations
with regard to these forward-looking statements or the occurrence of unanticipated
events.
hncmbodzqts g